US › Healthcare

Alzamend Neuro Inc (ALZN)

US · Healthcare · Biotechnology

$1.84+0.55%

Last close · 2026-09-17

Latest quarter · ended 2026-07-31

Revenue

Net profit

$-3.0M

EPS

$-0.68

EPS estimate

$-0.56

EPS came in at -0.68 against a street estimate of -0.56 — a miss of 21.4%.

Key statistics

Market cap

$8.8M

Forward P/E

0.0

P/B

1.48

Book value

$0.17

EPS (TTM)

$-2.09

52-week high

$2.68

52-week low

$0.84

50-day MA

$1.45

200-day MA

$1.59

Beta

0.24

Analyst view

Analysts rate Alzamend Neuro Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $26.00.

Shareholding

Insiders

2.68%

Institutions

56.76%

Largest institutional holders

Fund	Stake
KMT WEALTH MANAGEMENT, LLC	27.54%
Geode Capital Management, LLC	0.95%
Vanguard Fiduciary Trust Co	0.44%
Morgan Stanley - Brokerage Accounts	0.37%
Hartland & Co	0.21%
Tower Research Capital LLC	0.13%
Citigroup Inc	0.11%
UBS Group AG	0.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alzamend Neuro Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.